Table 1.
Ongoing Clinical Trials Registered on Clinicaltrials.gov for Blastic Plasmacytoid Dendritic Cell Neoplasm That are Actively Recruiting Patients as of 2/6/2022
| Agent | Phase | Key Eligibility | Clinicaltrials.gov ID Number |
|---|---|---|---|
| CD123 CAR T-cell therapy | 1 | Relapsed disease | NCT02159495 |
| NCT02623582 | |||
| NCT03766126 | |||
| NCT03203369 | |||
| NCT04109482 | |||
| IMGN632 (Anti-CD123 mAb-DNA-alkylating payload) | 1 | Relapsed disease | NCT03386513 |
| XmAB14045 (Bispecific CD123 × CD3 antibody) | 1 | Relapsed disease | NCT02730312 |
| Tagraxofusp-erzs + azacitidine + venetoclax | 1 | Relapsed disease | NCT03113643 |
| Venetoclax | 1 | Refractory or relapsed disease | NCT03485547 |
| Tagraxofusp + venetoclax + HCVAD/miniCVD | 2 | Treatment-naïve or relapsed disease | NCT04216524 |
| Flotetuzumab | 1 | Relapsed/refractory | NCT04681105 |
| Venetoxlax + decitabine | 2 | Relapsed/refractory | NCT03404193 |
Abbreviations: CAR, chimeric antigen receptor; HCVAD, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (Adriamycin), dexamethasone, methotrexate, and cytarabine; miniCVD, cyclophosphamide, vincristine sulfate and dexamethasone; mAb, monoclonal antibody.